MX2021008525A - Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. - Google Patents

Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia.

Info

Publication number
MX2021008525A
MX2021008525A MX2021008525A MX2021008525A MX2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A
Authority
MX
Mexico
Prior art keywords
polypeptides
interleukin
therapy
mutated
cytokine
Prior art date
Application number
MX2021008525A
Other languages
English (en)
Spanish (es)
Inventor
Ignacio Anegon
Carole Guillonneau
Erwan Mortier
Agnès Quemener
Original Assignee
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nantes filed Critical Univ Nantes
Publication of MX2021008525A publication Critical patent/MX2021008525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2021008525A 2019-01-15 2020-01-15 Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. MX2021008525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (1)

Publication Number Publication Date
MX2021008525A true MX2021008525A (es) 2021-11-12

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008525A MX2021008525A (es) 2019-01-15 2020-01-15 Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia.

Country Status (12)

Country Link
US (1) US20220098264A1 (US06656730-20031202-C00002.png)
EP (1) EP3911670A1 (US06656730-20031202-C00002.png)
JP (1) JP2022517029A (US06656730-20031202-C00002.png)
KR (1) KR20210121077A (US06656730-20031202-C00002.png)
CN (1) CN113508129A (US06656730-20031202-C00002.png)
AU (1) AU2020208909A1 (US06656730-20031202-C00002.png)
BR (1) BR112021013944A8 (US06656730-20031202-C00002.png)
CA (1) CA3126741A1 (US06656730-20031202-C00002.png)
IL (1) IL284868A (US06656730-20031202-C00002.png)
MX (1) MX2021008525A (US06656730-20031202-C00002.png)
SG (1) SG11202107606VA (US06656730-20031202-C00002.png)
WO (1) WO2020148338A1 (US06656730-20031202-C00002.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115819614B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于il34的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
JP2005506990A (ja) 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
ATE540973T1 (de) * 2004-07-22 2012-01-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
WO2007076354A2 (en) 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
SI2350129T1 (sl) 2008-08-25 2015-11-30 Amplimmune, Inc. Sestavki PD-1 antagonistov in postopek njihove uporabe
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
AU2014235750B2 (en) 2013-03-15 2018-05-17 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (IDO)
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
JP6769948B2 (ja) * 2014-07-17 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−３４ポリペプチド
CN106084030B (zh) * 2016-04-25 2019-11-08 北京大学 一种提高白细胞介素il-34热稳定性的方法

Also Published As

Publication number Publication date
IL284868A (en) 2021-08-31
WO2020148338A1 (en) 2020-07-23
AU2020208909A1 (en) 2021-07-29
SG11202107606VA (en) 2021-08-30
JP2022517029A (ja) 2022-03-03
EP3911670A1 (en) 2021-11-24
CA3126741A1 (en) 2020-07-23
CN113508129A (zh) 2021-10-15
US20220098264A1 (en) 2022-03-31
BR112021013944A2 (US06656730-20031202-C00002.png) 2021-11-21
KR20210121077A (ko) 2021-10-07
BR112021013944A8 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2021008525A (es) Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia.
MX2022001018A (es) Electrodos metalicos de bajo costo.
HK1138011A1 (en) Template-fixed peptidomimetics
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
TN2019000122A1 (en) Method for increasing the secretion levels of interleukin 2 and proteins derived from it
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
TWD210683S (zh) 電池
PH12018500492A1 (en) Charge/discharge control device, charge/discharge control system, and charge/discharge control method
MY176505A (en) Power adapter and terminal
MA38477A1 (fr) Mutéines d'interleukine 2 pour la propagation de lymphocytes t régulateurs
ECSP21077614A (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
EP3790561A4 (en) CELL POPULATIONS AND GENE EXPRESSION RELATED TO IN VITRO BETA CELL DIFFERENTIATION
WO2018222379A3 (en) SOLID STATE LITHIUM-METAL BATTERY BASED ON THREE-DIMENSIONAL ELECTRODE DESIGN
WO2020187340A3 (es) Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
EP4062951A4 (en) INJECTABLE HYDROGEL COMPOSITION FOR TRAPPING ENDOGENE PROGENIC OR STEM CELLS AND INDUCING VASCULAR DIFFERENTIATION OF TRAPPED CELLS
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
WO2019045805A3 (en) PROCESS FOR METALLIZING ELECTROCHEMICALLY ACTIVE POWDERS
CN206211399U (zh) 一种闭式卡具
WO2023076912A3 (en) Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
WO2019004795A3 (ko) 세포치료제의 유효성 평가 방법
WO2022261455A3 (en) Genetically-modified saccharomyces yeast strains as preventative and therapeutic agents
MX2019007115A (es) Proteina recombinante uk 114 novedosa en forma de polimero estable para uso en el tratamiento, diagnostico y prevencion de tumores solidos y sistemicos malignos.
CN208514093U (zh) 一种cnc工作台模具钢材校正装置
CN106340826B (zh) 一种闭式卡具